The role of personalized therapy in cancer associated depression among 10,673 patients.

12108 Background: Pharmacogenomics can help reduce the trial and error of antidepressant management in cancer patients. Depression is a major contributor to morbidity and mortality in cancer patients. Additionally genetic variation can affect metabolism for many antidepressants in various ways. CYP2D6 and CYP2C19 impact the pharmacokinetics of anti-depressants, which normally take weeks before clinical outcomes are achieved. Here we underline actionable phenotype frequencies stratified by ethnicity/race for CYP2C19and CYP2D6 in patients investigated for cancer, from a depression standpoint. Methods: A retrospective analysis of 10,673 patients genotyped for CYP2D6 and CYP2C19 was conducted (OneOme LLC, Minneapolis, MN). 1,616 tests were found to be ordered by oncologists and analyzed separately as a sample subset. Phenotype and allele frequencies were calculated and compared to self-reported ethnicity/race. Results: See table. Conclusions: This is the largest cohort to date to our knowledge that looks at the role of personalized therapy in cancer associated depression. Our data show that different tested ethnic group can show a predilection towards certain metabolic patterns. PMs may experience an increased risk of side effects with antidepressant therapy, whereas UMs may observe a reduction in treatment efficacy. Utilizing PGx to guide drug selection and dosing for cancer patients with depression can reduce trial and error, limit the burden of a very debilitating disease, and improve patients’ quality of life. Since our analyses showed very similar frequencies, we speculate that cancer patients suffering from depression can benefit from early identification. [Table: see text]